Novo Nordisk shares pop 5% after Wegovy receives U.S. approval for liver disease

cnbc.com/2025/08/18/novo-nordisk-shares-pop-5percent-after-wegovy-receives-us-approval-for-liver-disease.html

Shares of Novo Nordisk climbed almost 5% Monday after the company's blockbuster Wegovy obesity drug received accelerated approval from the U.S. Food and Drug Administration to treat a serious liver disease.
The company on Friday said that it was granted the approval for the treatment of…

This story appeared on cnbc.com, 2025-08-18 09:00:42.
The Entire Business World on a Single Page. Free to Use →